Colicin FY is a plasmid encoded toxin that recognizes a yersinia-specific outer membrane protein (YiuR) as a receptor molecule. We have previously shown that the activity spectrum of colicin FY comprises strains of the genus Yersinia. In this study, we analyzed the activity of colicin FY against 110 Yersinia enterocolitica isolates differing in geographical origin and source. All isolates were characterized through analysis of 16S rRNA genes, serotyping, biotyping, restriction profiling of genomic DNA, detection of virulence markers and susceptibility to antibiotics. This confirmed the broad variability of the collection, in which all 110 Y. enterocolitica isolates, representing 77 various strains, were inhibited by colicin FY. Although isolates showed variable levels of susceptibility to colicin FY, it was not associated with any strain characteristic. The universal susceptibility of Y. enterocolitica strains to colicin FY together with the absence of activity towards strains outside the Yersinia genus suggests potential therapeutic applications for colicin FY.

• MeSH
• bakteriální léková rezistence účinky léků   MeSH
• faktory virulence genetika   metabolismus   MeSH
• genom bakteriální * MeSH
• koliciny farmakologie   MeSH
• mikrobiální testy citlivosti MeSH
• Yersinia enterocolitica genetika   izolace a purifikace   metabolismus   MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• faktory virulence MeSH
• koliciny MeSH

The strain Escherichia coli Nissle 1917 (EcN) is widely used as an efficient probiotic in therapy and prevention of human infectious diseases, especially of the intestinal system. Concurrently, small adult pigs are being used as experimental omnivore models to study human gastrointestinal functions. EcN bacteria were applied to 6 adult healthy female pigs in a 2-week trial. 6 Control animals remained untreated. Altogether, 164 and 149 bacterial strains were isolated from smear samples taken from gastrointestinal mucosa in the experimental and control group, respectively. Each individual E. coli strain was then tested for the presence of 29 bacteriocin-encoding determinants as well as for DNA markers of A, B1, B2 and D phylogenetic groups. A profound reduction of E. coli genetic variance (from 32 variants to 13 ones, P = 0.0006) was found in the experimental group, accompanied by a lower incidence of bacteriocin producers in the experimental group when compared to control (21.3 and 34.9%, respectively; P = 0.007) and by changes in the incidence of individual bacteriocin types. The experimental administration of EcN strain was not sufficient for stable colonization of porcine gut, but induced significant changes in the enterobacterial microbiota.

• MeSH
• bakteriální geny MeSH
• bakteriociny genetika   MeSH
• Escherichia coli klasifikace   izolace a purifikace   MeSH
• fylogeneze MeSH
• genetická variace MeSH
• molekulární typizace MeSH
• prasata MeSH
• probiotika aplikace a dávkování   MeSH
• společenstvo * MeSH
• střevní sliznice mikrobiologie   MeSH
• zvířata MeSH
• Check Tag
• ženské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky MeSH
• práce podpořená grantem MeSH
• Názvy látek
• bakteriociny MeSH

A certain relationship was observed between the gastrointestinal system, arthritis and immune system. Patients with rheumatoid arthritis have an altered microflora composition and disturbed intestinal defensive barrier. Effect of probiotic bacteria (Colinfant; COL) with known favorable effect on intestinal microflora was determined on the methotrexate (MTX) treatment of adjuvant arthritis. Rats with adjuvant arthritis were administered methotrexate 0.5 mg/kg body mass 2-times weekly per os, COL 1 mL/kg body mass every second day per os, and a combination of MTX+COL for a period of 28 d from the immunization. Levels of serum albumin, body mass, changes in hind paw swelling, and arthrogram score were estimated in rats as variables of inflammation and destructive arthritis-associated changes. Treatment with MTX, as well as with the combination treatment with MTX+COL significantly inhibited both inflammation and destructive arthritis-associated changes. The combination treatment inhibited both the hind paw swelling and arthrogram score more remarkably than MTX alone; on the other hand, the difference between combination treatment and MTX alone was not significant. Treatment with COL alone had no effect on adjuvant arthritis in rats. Colinfant can increase the preventive effect of MTX treatment in rat adjuvant arthritis by improving its antiarthritic effects.

• MeSH
• antirevmatika aplikace a dávkování   MeSH
• artritida experimentální farmakoterapie   imunologie   terapie   MeSH
• Escherichia coli * fyziologie   MeSH
• kombinovaná terapie MeSH
• krysa rodu Rattus MeSH
• lidé MeSH
• methotrexát aplikace a dávkování   MeSH
• modely nemocí na zvířatech MeSH
• potkani inbrední LEW MeSH
• probiotika aplikace a dávkování   MeSH
• zvířata MeSH
• Check Tag
• krysa rodu Rattus MeSH
• lidé MeSH
• mužské pohlaví MeSH
• zvířata MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• Názvy látek
• antirevmatika MeSH
• methotrexát MeSH

Influence of intestinal colonization by a probiotic E. coli strain on the incidence of bacterial pathogens in stool and allergic symptoms during the 1st year of life was monitored in 3 groups: colonized children of allergic mothers (AC; n = 52), noncolonized children of allergic mothers (AN; n = 50), children of nonallergic mothers (NC; n = 42). Colinfant vaccine was administered within 2 d after birth, 3 x a week over a period of 4 weeks. Stool samples were examined after 2 d and at the age of 3, 6 and 12 months. At 3 months E. coli was present in 90 %, at 12 months in 73 % of AC. Pathogens were significantly less frequent on day 3 and at 3 months in AC vs. AN (15 vs. 61 %, p < 0.001; 15 vs. 38 %, p < 0.01) and vs. NC (15 vs. 63 %, p < 0.001; 15 vs. 53 %, p < 0.001). AC exhibited lower incidence of Staphylococcus epidermidis than AN on day 3 (6 vs. 31 %, p < 0.001) and of Klebsiella strains on day 3 and at 3 months (4 vs. 20 %, p < 0.05; 5 vs. 24 %, p < 0.01). AC showed a lower incidence of Pseudomonas aeruginosa than NC on day 3 (6 vs. 31 %, p < 0.01) and Klebsiella spp. on day 3 and at 3 months (4 vs. 22 %, p < 0.05; 5 vs. 45 %, p < 0.001). No significant differences were recorded after 6 and 12 months. The incidence of allergies was 3 % in AC, 26 % in AN (p < 0.01), and 10 % in NC.

• MeSH
• alergie etiologie   prevence a kontrola   MeSH
• aplikace orální MeSH
• bakteriální infekce komplikace   mikrobiologie   prevence a kontrola   MeSH
• Escherichia coli * MeSH
• incidence MeSH
• Klebsiella izolace a purifikace   MeSH
• kojenec MeSH
• lidé MeSH
• následné studie MeSH
• nemoci střev komplikace   mikrobiologie   prevence a kontrola   MeSH
• novorozenec MeSH
• přenašečství MeSH
• probiotika aplikace a dávkování   MeSH
• Pseudomonas aeruginosa izolace a purifikace   MeSH
• Staphylococcus epidermidis izolace a purifikace   MeSH
• střeva mikrobiologie   MeSH
• zdravotnické přehledy * MeSH
• Check Tag
• kojenec MeSH
• lidé MeSH
• novorozenec MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH

Probiotics modulate production of both cytokine and antimicrobial peptides. This effect can be regarded as a part of complex interplay between them and the host.

• MeSH
• Bifidobacterium imunologie   MeSH
• cytokiny metabolismus   MeSH
• kationické antimikrobiální peptidy metabolismus   MeSH
• Lactobacillus imunologie   MeSH
• lidé MeSH
• probiotika farmakologie   MeSH
• Check Tag
• lidé MeSH
• Publikační typ
• časopisecké články MeSH
• práce podpořená grantem MeSH
• přehledy MeSH
• Názvy látek
• cytokiny MeSH
• kationické antimikrobiální peptidy MeSH